Several statins are substrates for the multidrug resistance-associated protein 2 transporter, encoded by the ABCC2 gene. We analyzed in the Rotterdam Study whether the common polymorphisms À24C4T, 1249G4A and 3972C4T in the ABCC2 gene were associated with a dose decrease or switch to another cholesterol-lowering drug in simvastatin and atorvastatin users. These events could indicate an adverse effect or a too strong reduction in cholesterol level. We identified 1014 simvastatin and atorvastatin users during the period 1 January 1991 to 1 January 2010. Associations between genetic variation and the risk of these events were analyzed using Cox proportional hazards modelling. The ABCC2 À24C4T genotype (HR 1.32 95% CI 1.04-1.69) and the H12 haplotype versus the H2 haplotype (HR 1.49; 95% CI 1.06-2.09) were associated with these events in simvastatin users. A similar but not significant association was found in atorvastatin users. To conclude, genetic variation in the ABCC2 gene is associated with these events in simvastatin users.
Introduction
Statins are widely used to reduce morbidity and mortality in patients with hypercholesterolemia. 1 In general, statin therapy is safe and effective, although myopathy and rhabdomyolysis do occur as adverse reactions. Drug transporters, such as the P-gp and OATP1B1 transporter, are involved in the absorption, distribution and elimination of statins. Genetic variation in the ABCB1 gene, coding for the P-gp transporter, is associated with the cholesterol-lowering effect, 2, 3 and genetic variation in the SLCO1B1 gene, coding for the OATP1B1 transporter, is associated with myopathy. 4 Another transporter that is associated with statin response is the multidrug resistance-associated protein 2 (MRP2), encoded by the ABCC2 gene. 3 The MRP2 transporter is localized in the liver, intestine, kidney and bloodbrain barrier. 5 In the hepatocytes, MRP2 is an efflux transporter on the bile canalicular membrane. 6 Organic anions, such as pravastatin and atorvastatin are substrates for the MRP2 transporter. In MRP2-deficient rats, the biliary excretion of both oral and intravenous pravastatin was reduced, resulting in higher plasma concentrations. 7 Recently, Li et al. 8 reported that atorvastatin is a substrate for the MRP2 transporter, and simvastatin is not. In Caucasians, the most common single-nucleotide polymorphisms (SNPs) in the ABCC2 gene are À24C4T, 1249G4A and 3972C4T. Laechelt et al. 9 studied the effect of these SNPs and the haplotypes on protein expression and MRP2 transporter activity. The H2 haplotype (À24C/1249A/3972C) was associated with an increased protein expression and transport activity compared with the wild-type H1 haplotype (À24C/ 1249G/3972C) and the H9 (À24C/1249G/3972T) and H12 (À24T/1249G/3972T) haplotypes were associated with decreased protein expression and lower transport activity.
We studied whether genetic variation in the ABCC2 gene is associated with a dose decrease or a switch to another cholesterol-lowering drug during statin therapy. These events could be indicators of adverse effects or too strong reductions in cholesterol level. We also analyzed whether an interaction is present between genetic variation in the ABCC2 gene and the CYP3A4*1B polymorphism, similar to the interaction we previously found between genetic variation in the ABCB1 gene and the CYP3A4*1B polymorphism. 10 We also tested whether interactions between the genetic variation in the ABCC2 gene and the T521C polymorphism in the SLCO1B1 gene and the C3435T polymorphisms in the ABCB1 gene are present.
Materials and methods

Setting
Data for these analyses were obtained from the first cohort of the Rotterdam Study, a prospective population-based follow-up study of 7983 Caucasians aged 55 years and older in the suburb Ommoord in Rotterdam. Participants were invited between 1990 and 1993 and have been continuously followed since then. All participants of the Rotterdam Study gave written informed consent. Ethical approval was obtained from the Medical Ethical Committee of the Erasmus MC. The rationale, ethical approval and design of this study have been described before. 11 The seven pharmacies in Ommoord dispense the prescriptions of more than 99% of all participants. Information on all filled prescriptions from 1 January 1991 until 1 January 2010 was available and included the product name of the drug, the anatomical therapeutical chemical code, the amount dispensed, the prescribed dosage regimen and the date of dispensing.
Study sample
Simvastatin and atorvastatin were the most widely used statins in the Rotterdam Study. The number of users of other statins were not sufficient to have enough power. Therefore, all participants who had a prescription for simvastatin or atorvastatin in the period between 1 January 1991 and 1 January 2010 were included. Follow-up started at the date of the first prescription for simvastatin or atorvastatin in the database. Participants were followed until January 1st 2010, the end of the last prescription for simvastatin or atorvastatin, an increase in prescribed dose or the occurrence of an event, whichever came first. We included only study participants with at least 180 days of cholesterol-lowering drug use.
Outcome
We analyzed the occurrence of either a dose decrease or a switch to another cholesterol-lowering drug as an indicator of an adverse drug reaction or a too strong reduction in cholesterol level. The first time that a patient had a dose decrease or switched to another cholesterol-lowering drug (statins, fibrates, bile acid sequestrants, nicotinic acid, acipimox or ezetimibe) was regarded as an event. In the medical records we could retrieve that in 95 percent of the cases, the reason for these events was an adverse drug reaction or a too strong cholesterol reduction.
Cofactors
Age, gender and the prescribed dose of the first prescription for simvastatin or atorvastatin in the database were considered as potential confounders or effect modifiers for the association between the genetic variation in the ABCC2 gene and the occurrence of the events.
Genotyping
Participants were genotyped using the Infinium II HumanHap 550K Genotyping BeadChip version 3 (Illumina, San Diego, CA, USA) according to the manufacturer's instruction. Quality controls and results of the genotyping were previously described. 12 The tagging polymorphisms on the array were selected using an algorithm with which, in a Caucasian population, 90% of all phase I and II Hapmap polymorphisms are covered by at least one polymorphism on the array. We imputed the polymorphisms rs717620 (À24C4T), rs2273697 (1249G4A) and rs3740066 (3972C4T) using the Caucasian Hapmap population (release 22) with MACH software11. 13 The quality of imputations was checked by contracting imputed and actual genotypes at 78 844 polymorphisms not present on Illumina 550K for 437 individuals for whom these SNPs were directly typed using Affymetrix 500K (Santa Clara, CA, USA). The concordance rate was 99% for polymorphisms with the r 2 quality measure 40.9. Concordance was still high (94%) when the r 2 was between 0.5 and 0.9. The rs1871395 polymorphism in the SLCO1B1 gene on the Illumina 550K chip was selected, because this polymorphism is in complete LD with the T521C polymorphism in the SLCO1B1 gene. Genotyping CYP3A4*1B and the C3435T polymorphism in the ABCB1 gene were done using Taqman allelic discrimination assays on the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA) on 1 ng of genomic DNA extracted from leukocytes, as previously reported.
14 The ABCC2 haplotypes were estimated using PHASE version 2.1. 15, 16 Only haplotypes with a probability higher than 0.95 were included in the analyses. Beside the analyses with the most frequent H1 haplotype as reference, we also used the H2 haplotype (À24C/1249A/3972C) as a Genetic variation in ABCC2 and statin adverse effects reference allele, as this haplotype showed in vitro significantly increased transporter activity. 9 Statistical analysis A w 2 -test was used to test for deviations from HardyWeinberg equilibrium. Cox proportional hazard models were constructed to test for differences in the incidence of medication change events between ABCC2 genotypes and haplotypes. Additive models were used, in which we analyzed the association between the number of variant alleles or haplotypes and the occurrence of events. We tested for multiplicative interaction between the ABCC2 and CYP3A4*1B polymorphisms in the Cox models. A reduction in P-gp transporter activity will result in higher statin levels inside the hepatocyte and more substrate being available for the CYP3A4 metabolizing enzyme and therefore a larger effect of the CYP3A4*1B polymorphism. 10, 17, 18 We previously identified an interaction between the ABCB1 and the CYP3A4*1B polymorphism, and expected also an interaction with the ABCC2 polymorphisms as both P-gp and MRP2 are efflux transporters in the hepatocyte. We grouped the ABCC2 heterozygous and homozygous variant alleles to have sufficient numbers. We also tested for multiplicative interactions between the ABCC2 polymorphisms and the SLCO1B1 T521C polymorphism and the ABCB1 C3435T polymorphism in the Cox models, in the same way as we tested the interaction between ABCC2 and CYP3A4*1B. Analyses were performed with SPSS software (version 11.0.1; SPSS, Chicago, IL, USA).
Results
In the Rotterdam Study, we identified 1014 simvastatin and atorvastatin users, who were genotyped for the ABCC2 polymorphisms and used cholesterol-lowering drugs for more than 180 days ( Table 1 ). The majority of these patients (77.8%) were simvastatin users. The average time from start of simvastatin or atorvastatin therapy until an event or end of follow-up was 4.3 years (s.d. 4.0), and an event occurred in 230 patients (22.7%).
The quality of the imputation of the ABCC2 genotypes was good, with r 2 of 0.89, 1.00 and 0.99 for À24C4T, 1249G4A and 3972C4T, respectively. All genotype frequencies were in Hardy-Weinberg equilibrium. We could estimate the haplotypes with a probability of more than 0.95 for 92.4 percent of the study population. The haplotype frequencies are in line with those reported by Laechelt et al. In simvastatin users, the variant À24T allele was associated with a higher risk of a dose decrease or a switch to another drug ( Table 2 ). The risk of these events was higher for the H12 haplotype than for the H2 haplotype ( Table 3) . The other haplotypes were not significantly associated. For atorvastatin, no significant associations were found, although all associations were in the same direction as for simvastatin and combining the results of simvastatin and atorvastatin gave stronger associations.
We tested for multiplicative interaction between the CYP3A4*1B polymorphism and the ABCC2 polymorphism in simvastatin and atorvastatin users, and found a significant interaction between the 1249G4A and the CYP3A4*1B polymorphisms (HR ¼ 2.92; P ¼ 0.028). No interactions between the ABCC2 polymorphisms and the SLCO1B1 T521C polymorphism and between the ABCC2 polymorphisms and the ABCB1 C3435T polymorphisms were present.
Discussion
In this population based cohort study, we identified that the À24C4T polymorphism and the H12 (TGT) haplotype versus the H2 haplotype (CAC) in the ABCC2 gene are significantly associated with a dose decrease or a switch to another cholesterol-lowering drug, in simvastatin users. These events are most likely caused by adverse effects or too strong reductions in cholesterol levels. For atorvastatin, we did not find significant associations, although all associations were in the same direction as for simvastatin, suggesting that an association is present. Possibly, the number of atorvastatin users and with that the power to detect significant associations was too small.
The events in this study were chosen, because a physician facing an adverse drug reaction or a too strong reduction in cholesterol level has two possible options. First, the physician can lower the dose if he or she suspects a dose-effect relationship. Second, switching to another cholesterol-lowering drug is an option. In case of ineffective therapy the most likely decision is to increase the dose before switching to another drug and therefore follow-up ended at the time of the first dose increase. In a previous study, we used these endpoints to analyze the effect of genetic variation in the CYP3A4 and ABCB1 genes. 10 We found an association with the CYP3A4*1B polymorphism. In 21% percent of the events, we could retrieve the reason for the events in the electronic patient records of the general practitioner. Fifty-three percent of the events were due to an adverse drug reaction, 41% due to a too strong cholesterol reduction and 6% due to ineffectiveness of the statin. As the The number of halplotypes is given. As chromosomes are in pairs, each individual has two haplotypes. Therefore, the number of haplotypes doubles the 937 participants included. For 77 participants the haplotype was undetermined. Adjusted for: age, gender, starting dose. n: number of participants; N: number of events.
Genetic variation in ABCC2 and statin adverse effects ML Becker et al ABCB1 polymorphisms and the ABCC2 polymorphisms are not in linkage disequilibrium, the effect of the ABCC2 polymorphisms is not via the ABCB1 polymorphisms.
The association between the ABCC2 haplotypes and a dose decrease or a switch to another cholesterol-lowering drug in simvastatin users is in line with a previous publication in which the effects of these polymorphisms were studied in vitro. 9 The H2 haplotype (CAC) exhibited an increased protein expression and increased transporter activity compared with the wild-type H1 haplotype, while the H9 (CGT) and H12 (TGT) haplotypes exhibited a decreased protein expression and decreased efflux rates. We used the H2 haplotype as reference haplotype in our analyses, because the H2 haplotype had the highest transporter activity. Comparing the other haplotypes with the H2 haplotype, reduces the power needed to detect significant differences. No significant differences were found with the most frequent H1 haplotype.
The in vitro experiments by Laechelt et al. 9 suggest that the variant À24T allele is associated with decreased MRP2 transporter activity. We found that the variant À24T allele is associated with an increased risk for a dose decrease or a switch to another cholesterol-lowering drug in simvastatin users. It is possible that a decreased MRP2 transporter activity results in less elimination and therefore higher plasma levels and an increased risk for adverse drug reactions or a too strong reduction in cholesterol levels.
Our results are not in line with a recent publication by Li et al. 8 in which they report that atorvastatin is a substrate for both the P-gp and the MRP2 transporter, and that simvastatin is not a substrate for P-gp and MRP2. Their conclusion that simvastatin is not a substrate for P-gp is in contrast with both in vitro and in vivo studies reporting that simvastatin is a substrate for P-gp 19, 20 and studies reporting that genetic variation in the ABCB1 gene is associated with the pharmacokinetics 21 and the cholesterol-lowering effect of simvastatin. 2, 22 Similarly, the conclusion by Li et al. that simvastatin is not a substrate for the MRP2 transporter is in contrast with the results of our study.
We further analyzed the association between genetic variation in ABCC2 and the risk for a dose decrease or a switch to another cholesterol-lowering drug, by analyzing the interaction with the CYP3A4*1B polymorphism. The CYP3A4 enzyme and the P-gp and MRP2 transporters are all co-expressed in the cells of the intestine and in the hepatocytes. A decreased P-gp transporter activity will most likely result in a higher intracellular statin concentration and a stronger effect of the CYP3A4*1B polymorphism. 10 We analyzed whether this effect was also seen for the MRP2 transporter. We indeed found an interaction between the 1249G4A and the CYP3A4*1B polymorphism. Both a decreased P-gp and a decreased MRP2 transporter activity result in a stronger effect of the CYP3A4*1B polymorphism. We did not find significant interactions between the ABCC2 polymorphisms and the SLCO1B1 T521C polymorphism and the ABCB1 C3435T polymorphism. In previous studies, the SLCO1B1 T521C polymorphism was also associated with adverse effects during statin therapy, 4, 23 and the effect seems to be larger than the effect of the genetic variation in the ABCC2 gene. Nevertheless, we did not find an interaction between the SLCO1B1 and ABCC2 polymorphisms. As we tested multiple interactions, there is a chance that the interaction between the ABCC2 polymorphisms and CYP3A4*1B is a false-positive one. Many transporters and metabolizing enzymes have a role in the absorption, distribution, metabolism and elimination of simvastatin and atorvastatin. The effect of the ABCC2 À24C4T polymorphism in simvastatin users is smaller than the effect of the CYP3A4*1B polymorphism, but larger than the effect of the ABCB1 3435C4T polymorphism. 10 We did not find a significant association for the ABCC2 1249G4A and 3972C4T polymorphisms. It is possible that the power of the study and the influence of these polymorphisms are too modest to find a significant association. We found an interaction between the ABCC2 1249G4A, and the CYP3A4*1B polymorphism, but not between the ABCC2 À24C4T and the CYP3A4*1B polymorphism. The ABCC2 1249G4A genotype was not significantly associated with the occurrence of events in simvastatin users, but a nonsignificant trend was present. We cannot clarify why we found an interaction with the 1249G4A polymorphism, but not for the À24C4T polymorphism. Other studies must further clarify the role of the MRP2 transporter in the cholesterol-lowering effect of statins and the interaction it has with metabolizing enzymes and other transporters. The effect of genetic variation in the individual genes coding for these transporters and metabolizing enzymes is probably not strong enough to be applicable in clinical practice. However, by combining the effects of individual transporters end enzymes, the predictability of adverse effects and the cholesterol-lowering effect may improve.
In this study, we used dose decreases and switches to another cholesterol-lowering drug as an event. We assumed that these events were associated with adverse effects or a too strong reduction in cholesterol level. However, we could not retrieve the reason for all the events in the patient records. Part of these events will be caused by other reasons such as ineffective drug therapy. In the patient records, we could retrieve that only a minority of the events was due to ineffectiveness. This misclassification may give an underestimation of the true effect. On the other hand, we probably will have missed adverse drug reactions, for example, if the adverse drug reaction resulted in discontinuation of cholesterol-lowering therapy. As the identification of the events is independent of the genotypes, this will not have biased the associations.
In conclusion, in simvastatin users the ABCC2 À24C4T genotype and the H12 (À24T/1249G/3972T) haplotype versus the H2 haplotype (À24C/1249A/3972C) are significantly associated with an increased risk of a dose decrease or a switch to another cholesterol-lowering drug. These events are an indication for an adverse drug reaction or a too strong reduction in cholesterol level. For atorvastatin, we did not find significant associations, although the directions of the effects were the same for simvastatin, suggesting that genetic variation in the ABCC2 gene might also be associated with these events in atorvastatin users.
